229 lines
56 KiB
HTML
229 lines
56 KiB
HTML
<!DOCTYPE html>
|
||
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
|
||
<meta charset="utf-8"/>
|
||
<meta content="pandoc" name="generator"/>
|
||
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
|
||
<title>08 May, 2021</title>
|
||
<style type="text/css">
|
||
code{white-space: pre-wrap;}
|
||
span.smallcaps{font-variant: small-caps;}
|
||
span.underline{text-decoration: underline;}
|
||
div.column{display: inline-block; vertical-align: top; width: 50%;}
|
||
</style>
|
||
<title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
|
||
<body>
|
||
<h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
|
||
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
|
||
<ul>
|
||
<li><a href="#from-preprints">From Preprints</a></li>
|
||
<li><a href="#from-clinical-trials">From Clinical Trials</a></li>
|
||
<li><a href="#from-pubmed">From PubMed</a></li>
|
||
<li><a href="#from-patent-search">From Patent Search</a></li>
|
||
</ul>
|
||
<h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
|
||
<ul>
|
||
<li><strong>How anxiety predicts interpersonal curiosity during the COVID-19 pandemic: The mediation effect of interpersonal distancing and autistic tendency</strong> -
|
||
<div>
|
||
With the worldwide implementation of quarantine regulations to suppress the spread of the COVID-19, anxiety, interpersonal distancing and autistic tendency may decrease individuals’ desire to seek interpersonal information and thus might have negative effects on their interpersonal curiosity. Through behavioral paradigms and scales, two studies were conducted (Study 1: n = 570; Study 2: n = 501). We explored the prediction effects of anxiety to interpersonal curiosity and the mediating roles played by interpersonal distance and autistic tendency during the COVID-19. We found that interpersonal distance and autistic tendency mediated and suppressed the positively predictive effect of state anxiety on interpersonal curiosity. Our research provides insights into the relationships among anxiety, curiosity, interpersonal distancing, and autistic tendency during the COVID-19 pandemic. Our research provides insights into the relationships among anxiety, curiosity, interpersonal distancing, and autistic tendency during the COVID-19 pandemic.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://psyarxiv.com/43fcg/" target="_blank">How anxiety predicts interpersonal curiosity during the COVID-19 pandemic: The mediation effect of interpersonal distancing and autistic tendency</a>
|
||
</div></li>
|
||
<li><strong>Effects of COVID-19 Mental Health Interventions among Community-based Children, Adolescents, and Adults: A Living Systematic Review of Randomised Controlled Trials</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Background: Scalable interventions to address COVID-19 mental health are needed. Our objective was to assess effects of mental health interventions for community-based children, adolescents, and adults. Methods: We searched 9 databases (2 Chinese-language) from December 31, 2019 to March 22, 2021. We included randomised controlled trials with non-hospitalised, non-quarantined participants of interventions to address COVID-19 mental health challenges. We synthesized results descriptively but did not pool quantitatively due to substantial heterogeneity of populations and interventions and concerns about risk of bias. Findings: We identified 9 eligible trials, including 3 well-conducted, well-reported trials that tested interventions designed specifically for COVID-19 mental health challenges, plus 6 trials of standard interventions (e.g., individual or group therapy, expressive writing, mindfulness recordings) minimally adapted for COVID-19, all with risk of bias concerns. Among the 3 COVID-19-specific intervention trials, one (N = 670) found that a self-guided, internet-based cognitive-behavioural intervention targeting dysfunctional COVID-19 worry significantly reduced COVID-19 anxiety (standardized mean difference [SMD] 0.74, 95% CI 0.58 to 0.90) and depression symptoms (SMD 0.38, 95% CI 0.22 to 0.55) in Swedish general population participants. A lay-delivered telephone intervention for homebound older adults in the United States (N = 240) and a peer-moderated education and support intervention for people with a rare autoimmune condition from 12 countries (N = 172) significantly improved anxiety (SMD 0.35, 95% CI 0.09 to 0.60; SMD 0.31, 95% CI 0.03 to 0.58) and depressive symptoms (SMD 0.31, 95% CI 0.05 to 0.56; SMD 0.31, 95% CI 0.07 to 0.55) 6-weeks post-intervention, but these were not significant immediately post-intervention. No trials in children or adolescents were identified. Interpretation: Internet-based programs for the general population and lay- or peer-delivered interventions for vulnerable groups may be effective, scalable options for public mental health in COVID-19. More well-conducted trials, including for children and adolescents, are needed.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.04.21256517v1" target="_blank">Effects of COVID-19 Mental Health Interventions among Community-based Children, Adolescents, and Adults: A Living Systematic Review of Randomised Controlled Trials</a>
|
||
</div></li>
|
||
<li><strong>Multi-site Evaluation of SARS-CoV-2 Spike Mutation Detection Using a Multiplex Real-time RT-PCR Assay</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Background. SARS-CoV-2 causes COVID-19, which can be fatal and is responsible for a global pandemic. Variants with increased transmissibility or the potential to evade immunity have emerged and represent a threat to global pandemic control. Variants of concern (VOC) can be identified by sequencing of viral RNA, or by more rapid methods for detection of subsets of signature mutations. Methods. We developed a multiplex, real-time RT-PCR assay (cobas SARS-CoV-2 Variant Set 1) for the qualitative detection and differentiation of three key SARS-CoV-2 mutations in the viral spike protein: del 69-70, E484K and N501Y. Analytical sensitivity and accuracy were evaluated at three testing sites using clinical specimens from patients infected with SARS-CoV-2 variants belonging to several different lineages, including B.1.1.7, B.1.351, and P.1. Results. The limit of detection for E484K was between 180 and 620 IU/mL for the three different isolates tested. For N501Y, the LOD was between 270 and 720 IU/mL (five isolates), while for del 69-70, it was 80 - 92 IU/mL (two isolates). Valid test results were obtained with all clinical specimens that were positive using routine diagnostic tests. Compared to sequencing (Sanger and next-generation), test results were 100% concordant at all three loci; no false positive or false negative results were observed. Conclusions. Data collected at three independent laboratories indicates excellent performance and concordance of cobas SARS-CoV-2 Variant Set 1 with sequencing. New sets of primers and probes that target additional loci can be rapidly deployed in response to the identification of other emerging variants.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.05.21254713v1" target="_blank">Multi-site Evaluation of SARS-CoV-2 Spike Mutation Detection Using a Multiplex Real-time RT-PCR Assay</a>
|
||
</div></li>
|
||
<li><strong>Japan’s Covid mitigation strategy and its epidemic prediction</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
The COVID-19 epidemic curve in Japan was constructed based on daily reported data from January 14, 2020 until April 20, 2021. A SEIR compartmental model was used for the curve fitting by updating the estimation per wave. In the current vaccination pace of 1/1000, restrictions (state of emergency in Japan) would be repeated 4 times until the end of next March. In the case of 1/500, another round of restriction would be required in the summer 2021, after which the infection would be mitigated. In the case of 1/250, there would be no need for restriction after the current spring restriction. The scenario of completing the vaccination of 110 million people by the end of March 2020 corresponds to the case of 1/250 in this curve. When considering the likely spread of variant with greater infectiousness (here we assume 1.3 times greater than the original virus), 1/500 pace of vaccination would not be enough to contain it and need several series of restrictions. There are currently several variants of concern that are already spreading in urban areas in this country. In the new stage of the replacement of variants, if the vaccination pace could not be quadrupled from the current pace, Japan could not become a zero covid (zero corona) country at least one year.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.06.21256476v1" target="_blank">Japan’s Covid mitigation strategy and its epidemic prediction</a>
|
||
</div></li>
|
||
<li><strong>Precision Health Diagnostic and Surveillance Network uses S Gene Target Failure (SGTF) combined with sequencing technologies to identify emerging SARS-CoV-2 variants.</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Several genomic epidemiology tools have been developed to track the public and population health impact of SARS-CoV-2 community spread worldwide. A SARS-CoV-2 Variant of Concern (VOC) B.1.1.7, known as 501Y.V1, which shows increased transmissibility, has rapidly become the dominant VOC in the United States (US). Our objective was to develop an evidenced-based genomic surveillance algorithm that combines RT-PCR and sequencing technologies to identify VOCs. Deidentified data were obtained from 508,969 patients tested for COVID-19 with the TaqPath COVID-19 RT-PCR Combo Kit (ThermoFisher) in four CLIA certified clinical laboratories in Puerto Rico (n=86,639) and in three CLIA certified clinical laboratories in the US (n=422,330). TaqPath data revealed a frequency of S Gene Target Failure (SGTF) >47% for the last week of March 2021, in both Puerto Rico and US laboratories. The monthly frequency of SGTF in Puerto Rico steadily increased exponentially from 4% in November 2020 to 47% in March 2021.The weekly SGTF rate in US samples was high (>8%) from late December to early January, and then also increased exponentially through April (48%). The exponential increase in SGFT prevalence in Puerto Rico is concurrent with a sharp increase in VOCs among all SARS-CoV-2 sequences from Puerto Rico uploaded to GISAID (n=461). B.1.1.7 frequency increased from <1% in the last week of January 2021 to 51.5% of viral sequences from Puerto Rico collected in the last week of March 2021. The exponential increase in SGTF and B.1.1.7 prevalence in Puerto Rico and US requires an urgent response. According to the proposed evidence-based algorithm, approximately 50% of all positive samples should be managed as potential B.1.1.7 carriers with VOC quarantine and contact tracing protocols while their lineage is confirmed by WGS in surveillance laboratories. Patients infected with VOCs should be effectively triaged for isolation, contact tracing and follow-up treatment purposes.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.04.21256012v1" target="_blank">Precision Health Diagnostic and Surveillance Network uses S Gene Target Failure (SGTF) combined with sequencing technologies to identify emerging SARS-CoV-2 variants.</a>
|
||
</div></li>
|
||
<li><strong>Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
It is unclear whether prior endemic coronavirus infections affect COVID-19 severity. Here, we show that in cases of fatal COVID-19, antibody responses to the SARS-COV-2 spike are directed against epitopes shared with endemic beta-coronaviruses in the S2 subunit of the SARS-CoV-2 spike protein. This immune response is associated with the compromised production of a de novo SARS-CoV-2 spike response among individuals with fatal COVID-19 outcomes.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.04.21256571v1" target="_blank">Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses</a>
|
||
</div></li>
|
||
<li><strong>Multicentric Evaluation of a Novel Point of Care Electrochemical ELISA Platform for SARS-CoV-2 Specific IgG and IgM Antibody Assay</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
New diagnostics technologies for the efficient detection and quantification of SARS-CoV-2 Antibodies is very crucial to manage the COVID-19 pandemic, especially in the context of emerging vaccination paradigms. Herein, we report on a novel point-of-care Electrochemical ELISA platform with disposable screen printed electrodes functionalized with SARS-CoV-2 Spike Glycoprotein S1, to enable fast and accurate quantitative estimation of total antibody concentration (IgG and IgM) in clinical samples. The quantification is performed with a comparison of electrochemical redox current against the current produced by the spiked monoclonal antibodies with known concentration. The assay is validated through multicentric evaluation against 3 different FDA authorized Laboratory standard techniques, using both EDTA whole blood and serum samples. We demonstrate that the proposed assay has excellent sensitivity and specificity, making it a suitable candidate for epidemiological surveys and quantification of antibodies in COVID-19 vaccination programs.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.04.21256472v1" target="_blank">Multicentric Evaluation of a Novel Point of Care Electrochemical ELISA Platform for SARS-CoV-2 Specific IgG and IgM Antibody Assay</a>
|
||
</div></li>
|
||
<li><strong>Interpretation of temporal and spatial trends of SARS-CoV-2 RNA in San Francisco Bay Area wastewater</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Wastewater surveillance for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA can be integrated with COVID-19 case data to inform timely pandemic response. However, more research is needed to apply and develop systematic methods to interpret the true SARS-CoV-2 signal from noise introduced in wastewater samples (e.g., from sewer conditions, sampling and extraction methods, etc.). In this study, raw wastewater was collected weekly from five sewersheds and one residential facility, and wastewater SARS-CoV-2 concentrations were compared to geocoded COVID-19 clinical testing data. SARS-CoV-2 was reliably detected (95% positivity) in frozen wastewater samples when reported daily new COVID-19 cases were 2.4 or more per 100,000 people. To adjust for variation in sample fecal content, crAssphage, pepper mild mottle virus, Bacteroides ribosomal RNA (rRNA), and human 18S rRNA were evaluated as normalization biomarkers, and crAssphage displayed the least spatial and temporal variability. Both unnormalized SARS-CoV-2 RNA signal and signal normalized to crAssphage had positive and significant correlation with clinical testing data (Kendall9s Tau-b=0.43 and 0.38, respectively). Locational dependencies and the date associated with testing data impacted the lead time of wastewater for clinical trends, and no lead time was observed when the sample collection date (versus the result date) was used for both wastewater and clinical testing data. This study supports that trends in wastewater surveillance data reflect trends in COVID-19 disease occurrence and presents approaches that could be applied to make wastewater signal more interpretable and comparable across studies.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.04.21256418v1" target="_blank">Interpretation of temporal and spatial trends of SARS-CoV-2 RNA in San Francisco Bay Area wastewater</a>
|
||
</div></li>
|
||
<li><strong>Risk assessment for long and short range airborne transmission of SARS-CoV-2, indoors and outdoors, using carbon dioxide measurements.</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
A quantitative analysis of the viral transmission risk in public spaces al- lows us to identify the dominant mechanisms that a proactive public health policy can act upon to reduce risk, and to evaluate the reduction of risk that can be obtained. The contribution of public spaces to the propa- gation of SARS-CoV-2 can be reduced to a level necessary for a declining epidemic, i.e. an overall reproduction rate below one. Here, we revisit the quantitative assessment of indoor and outdoor transmission risk. We show that the long-range aerosol transmission is controlled by the flow rate of fresh air and by the mask filtering quality, and is quantitatively re- lated to the CO2 concentration, regardless the room volume and the num- ber of people. The short-range airborne transmission is investigated ex- perimentally using dedicated dispersion experiments performed in two shopping malls. Exhaled aerosols are dispersed by turbulent draughts in a cone, leading to a concentration inversely proportional to the squared dis- tance and to the flow velocity. We show that the average infection dose, called the viral quantum, can be determined from epidemiological data in a manner consistent with biological experimental data. Practical implications. The results provide quantitative guidance useful for making rational public health policy decisions to prevent the dominant routes of viral transmission through reinforced ventilation, air purification, mechanical dispersion using fans, and incentivizing the wear- ing of correctly fitted, quality facial masks (surgical masks, possibly cov- ered by another fabric mask, or non-medical FFP2 masks). Taken to- gether, such measures significantly reduce the airborne transmission risk of SARS-CoV-2.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.04.21256352v1" target="_blank">Risk assessment for long and short range airborne transmission of SARS-CoV-2, indoors and outdoors, using carbon dioxide measurements.</a>
|
||
</div></li>
|
||
<li><strong>Risk of vaccine preventable diseases in UK migrants: a serosurvey and concordance analysis, 2020</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
We conducted a serosurvey in 2020, amongst 149 adult migrants living in the United Kingdom, to determine seroprotection rates for measles, varicella zoster, and rubella. Findings suggest a gap in seroprotection against measles (89.3%). Younger migrants and those from Europe and Central Asia may be more susceptible; self-reported vaccine/disease status is a poor predictor of seroprotection. Understanding factors associated with seroprotection among migrants is critical for informing the delivery of SARS-CoV-2 vaccine.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.04.21253031v1" target="_blank">Risk of vaccine preventable diseases in UK migrants: a serosurvey and concordance analysis, 2020</a>
|
||
</div></li>
|
||
<li><strong>Supporting Families to Protect Child Health: Parenting Quality and Household Needs During the COVID-19 Pandemic</strong> -
|
||
<div>
|
||
Background: Supportive parenting is critical for promoting healthy child development in the face of stressors, such as those occurring during COVID-19. Here, we address a knowledge gap regarding specific household risk factors associated with parenting quality during the pandemic and incorporate first-person accounts of family challenges and needs. Methods: Mixed methods were applied to data collected between April 14th - 28th, 2020 from the “Parenting During the Pandemic” survey. Participants included 656 primary caregivers (e.g., mothers, fathers, foster parents) of least one child age 1.5-8 years of which 555 (84.6%) responded to at least one parenting questionnaire. Parenting quality was assessed across stressful, negative, and positive parenting dimensions. Household risk was examined across pandemic-linked (e.g., caregiver depression, unmet childcare needs) and stable factors (i.e., annual income, mental illness history). Significant correlates were examined with regressions in Mplus. Thematic analysis identified caregiver challenges and unmet needs from open-ended questions. Findings: Caregiver depression, higher child parity, unmet childcare needs, and relationship distress predicted lower-quality parenting. Caregiver depression was the most significant predictor across every parenting dimension, with analyses indicating medium effect sizes, ds = .39 - .73. Qualitative findings highlighted severe strains on parent capacities including managing psychological distress, limited social supports, and too much unstructured time. Interpretations: Lower quality parenting during COVID-19 is associated with multiple household and pandemic risk factors, with caregiver depression consistently linked to parent-child relationship disruptions. Focused efforts are needed to address caregiver mental health to protect child health as part of the pandemic response.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://psyarxiv.com/u5xzw/" target="_blank">Supporting Families to Protect Child Health: Parenting Quality and Household Needs During the COVID-19 Pandemic</a>
|
||
</div></li>
|
||
<li><strong>SARS-CoV-2 variants of concern, variants of interest and lineage A.27 are on the rise in Côte d’Ivoire</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
SARS-CoV-2 variants of concern (VOC) and variants of interest (VOI) are heavily altering the COVID-19 pandemic9s course due to their increased transmissibility, virulence and immune escape abilities. Data on their spread in western sub-Saharan Africa is however still scarce. We therefore sequenced viral genomes from SARS-CoV-2 cases identified in central and northern Côte d9Ivoire between May 2020 and March 2021. We report the introduction of VOC B.1.1.7 as early as mid-January 2021, followed by detection of a single case of VOC B.1.351, as well as VOI B.1.525. Since early 2021 VOC/VOI are gradually dominating the SARS-CoV-2 virus pool in Côte d9Ivoire, as seen in other regions of the world. Intriguingly, we also find that another lineage, A.27, has also been on the rise over the same period. In sum, this study highlights again the extremely rapid local diffusion of VOC, VOI and possibly A.27, and the importance of further reinforcing capacities for genomic surveillance on the African continent.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.06.21256282v1" target="_blank">SARS-CoV-2 variants of concern, variants of interest and lineage A.27 are on the rise in Côte d’Ivoire</a>
|
||
</div></li>
|
||
<li><strong>Extracorporeal membrane oxygenation in COVID-19 patients and in-hospital mortality: results from the Brazilian Registry using a propensity score matched analysis</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Around 5% of coronavirus disease 2019 (COVID-19) patients develop critical disease, with severe pneumonia and acute respiratory distress syndrome (ARDS). In these cases, extracorporeal membrane oxygenation (ECMO) may be considered when conventional therapy fails. This study aimed to assess the clinical characteristics and in-hospital outcomes of COVID-19 patients with ARDS refractory to standard lung-protective ventilation and pronation treated with ECMO support and to compare them to patients who did not receive ECMO. Patients were selected from the Brazilian COVID-19 Registry. At the moment of the analysis, 7,646 patients were introduced in the registry, eight of those received ECMO support (0.1%). The convenience sample of patients submitted to ECMO was compared to control patients selected by genetic matching for gender, age, comorbidities, pronation, ARDS and hospital, in a 5:1 ratio. From the 48 patients included in the study, eight received ECMO and 40 were matched controls. There were no significant differences in demographic, clinical and laboratory characteristics. Mortality was higher in the ECMO group (n = 7; 87.5%) when compared with controls (n = 17; 42.5%), (p=0.048). In conclusion, COVID 19 patients with ARDS refractory to conventional therapy who received ECMO support had worse outcomes to patients who did not receive ECMO. Our findings are not different from previous studies including a small number of patients, however there is a huge difference from Extracorporeal Life Support Organization results, which encourages us to keep looking for our best excellence.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.05.21256475v1" target="_blank">Extracorporeal membrane oxygenation in COVID-19 patients and in-hospital mortality: results from the Brazilian Registry using a propensity score matched analysis</a>
|
||
</div></li>
|
||
<li><strong>A Rapid and Reliable Liquid Chromatography/Mass Spectrometry Method for SARS-CoV-2 Diagnostics from Gargle Solutions and Saliva</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
We describe a rapid liquid chromatography/mass spectrometry (LC/MS) method for the direct detection and quantitation of SARS-CoV-2 nucleoprotein in gargle solutions and saliva. The method is based on a multiple-reaction monitoring (MRM) mass spectrometry approach with a total cycle time of 5 minutes per analysis and allows the detection and accurate quantitation of SARS-CoV-2 nucleoprotein as low as 500 amol/ul. We improved the sample preparation protocol of our recent piloting SARS-CoV-2 LC/MS study regarding sensitivity, reproducibility, and compatibility with a complementary reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) analysis of the same sample. The aim of this work is to promote diagnostic tools that allow identifying and monitoring SARS-CoV-2 infections by LC/MS methods in a routine clinical environment.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.05.21256257v1" target="_blank">A Rapid and Reliable Liquid Chromatography/Mass Spectrometry Method for SARS-CoV-2 Diagnostics from Gargle Solutions and Saliva</a>
|
||
</div></li>
|
||
<li><strong>The first GAEN-based COVID-19 contact tracing app in Norway identifies 80% of close contacts in “real life” scenarios.</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
The COVID-19 response in most countries depends on testing, isolation, contact tracing, and quarantine, which is labor- and time consuming. Therefore, several countries worldwide launched Bluetooth based apps as supplemental tools. We evaluated the new Norwegian GAEN (Google Apple Exposure Notification) based contact tracing app 9Smittestopp9 under two relevant simulated scenarios, namely standing in a queue and riding public transport. We compared two configurations (C1: 58/63 dBm; C2: 58/68 dBm) with multiple weights (1.0-2.5) and time thresholds (10-15 min), by calculating notification rates among close contacts (≤2 meters, ≥15 min) and other non-close contacts. In addition, we estimated the effect of using different operating systems and locations of phone (hand/pocket) using Chi2. C2 resulted in significantly higher notification rates than C1 (p-value 0.05 - 0.005). The optimal setting resulted in notifications among 80% of close contacts and 34% of other contacts, using C2 with weights of 2.0 for the low and 1.5 for the middle bucket with a 13-minutes time threshold. Among other contacts, the notification rate was 67% among those ≤2 meters for <15 minutes compared to 19% among those >2 meters (p=0.004). Significantly (p-values 0.046 - 0.001) lower notification rates were observed when using the iOS operating systems or carrying the phone in the pocket instead of in the hand. This study highlights the importance of testing and optimizing the performance of contact tracing apps under 9real life9 conditions to optimized configuration for identifying close contacts.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.06.21253948v1" target="_blank">The first GAEN-based COVID-19 contact tracing app in Norway identifies 80% of close contacts in “real life” scenarios.</a>
|
||
</div></li>
|
||
</ul>
|
||
<h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
|
||
<ul>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Drug: GT0918 tablets or placebo<br/><b>Sponsor</b>: Suzhou Kintor Pharmaceutical Inc,<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19</strong> - <b>Conditions</b>: Covid19; COVID-19 Prevention<br/><b>Interventions</b>: Drug: Hydroxychloroquine (HCQ); Other: Standard care; Other: Placebo<br/><b>Sponsor</b>: Postgraduate Institute of Medical Education and Research<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Biological: low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell); Biological: high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell); Biological: placebo<br/><b>Sponsors</b>: National Vaccine and Serum Institute, China; Lanzhou Institute of Biological Products Co., Ltd; Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd.; Zhengzhou University<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Drug: Niclosamide; Drug: Placebo<br/><b>Sponsor</b>: AzurRx BioPharma, Inc.<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>tDCS for Post COVID-19 Fatigue</strong> - <b>Condition</b>: Post Covid-19 Patients<br/><b>Intervention</b>: Device: Transcranial Direct Current Stimulation<br/><b>Sponsor</b>: Thorsten Rudroff<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Immunobridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Biological: 3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated; Biological: 3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated; Biological: 3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated; Biological: 2 doses of vaccine<br/><b>Sponsors</b>: China National Biotec Group Company Limited; Beijing Institute of Biological Products Co Ltd.<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Convalescent Plasma as Adjunct Therapy for COVID-19</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Biological: Convalescent plasma treatment<br/><b>Sponsors</b>: National Institute of Health Research and Development, Ministry of Health Republic of Indonesia; Indonesian Red Cross; Eijkman Institute for Molecular Biology<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Drug: Selenium (as Selenious Acid); Other: Placebo<br/><b>Sponsors</b>: CHRISTUS Health; Pharco Pharmaceuticals<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Protecting Our Community: COVID-19 Testing</strong> - <b>Conditions</b>: SARS-CoV-2; Covid19<br/><b>Intervention</b>: Diagnostic Test: Home-based SARS-CoV-2 test kit<br/><b>Sponsors</b>: Montana State University; National Institute of General Medical Sciences (NIGMS); University of Washington; Fred Hutchinson Cancer Research Center; Salish Kootenai College<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Detection of SARS-CoV-2 in Nasopharyngeal Swabs by Using Multi-Spectral Screening System</strong> - <b>Condition</b>: Covid19<br/><b>Intervention</b>: Diagnostic Test: AP-23<br/><b>Sponsor</b>: Fable Biyoteknoloji San ve Tic A.S<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Estradiol and Progesterone in Hospitalized COVID-19 Patients</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Other: Placebo injection and placebo pill; Drug: Estradiol Cypionate 5 MG/ML; Drug: Progesterone 200 MG Oral Capsule<br/><b>Sponsor</b>: Tulane University<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Drug: Ensovibep; Drug: Placebo<br/><b>Sponsor</b>: Molecular Partners AG<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>#SafeHandsSafeHearts: An eHealth Intervention for COVID-19 Prevention and Support</strong> - <b>Condition</b>: Covid19<br/><b>Intervention</b>: Behavioral: eHealth for Covid-19 prevention and support<br/><b>Sponsor</b>: University of Toronto<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 Vaccination Take-Up</strong> - <b>Conditions</b>: Covid19; Vaccination<br/><b>Interventions</b>: Behavioral: Financial incentives; Behavioral: Convenient scheduling link; Behavioral: Race concordant; Behavioral: Gender concordant<br/><b>Sponsors</b>: University of Southern California; Contra Costa Health Services; J-PAL North America, State and Local Innovation Initiative; National Bureau of Economic Research Roybal Center; National Institute on Aging (NIA)<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Drug: Niclosamide; Drug: Placebo<br/><b>Sponsors</b>: Cambridge University Hospitals NHS Foundation Trust; LifeArc; Kidney Research UK (KRUK); UNION therapeutics; Addenbrookes Charitable Trust<br/><b>Recruiting</b></p></li>
|
||
</ul>
|
||
<h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
|
||
<ul>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>beta-D-N 4-hydroxycytidine (NHC) Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells</strong> - Mutagenic ribonucleosides can act as broad-based antiviral agents. They are metabolized to the active ribonucleoside triphosphate form and concentrate in the genomes of RNA viruses during viral replication. β-D-N 4-hydroxycytidine (NHC, the initial metabolite of molnupiravir) is more than 100-fold more active than ribavirin or favipiravir against SARS-CoV-2, with antiviral activity correlated to the level of mutagenesis in virion RNA. However, NHC also displays host mutational activity in an…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Identification of phytocompounds from Houttuynia cordata Thunb. as potential inhibitors for SARS-CoV-2 replication proteins through GC-MS/LC-MS characterization, molecular docking and molecular dynamics simulation</strong> - The COVID-19 pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a massive viral disease outbreak of international concerns. The present study is mainly intended to identify the bioactive phytocompounds from traditional antiviral herb Houttuynia cordata Thunb. as potential inhibitors for three main replication proteins of SARS-CoV-2, namely Main protease (Mpro), Papain-Like protease (PLpro) and ADP ribose phosphatase (ADRP) which control the replication process. A…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Current understanding on molecular drug targets and emerging treatment strategy for novel coronavirus-19</strong> - SARS-CoV-2 is an enveloped positive-sense RNA virus, contain crown-like spikes on its surface, exceptional of large RNA genome, and a special replication machinery. Common symptoms of SARS-CoV-2 include cough, common cold, fever, sore throat, and a variety of severe acute respiratory disease (SARD) such as pneumonia. SARS-CoV-2 infects epithelial cells, T-cells, macrophages, and dendritic cells and also influences the production and implantation of pro-inflammatory cytokines and chemokines….</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Covid-19 Clinical Course and Blood Groups: Turkish Population-Based Study</strong> - CONCLUSION: Our study revealed that ABO and Rh blood groups do not have any impact on the rate of hospital admission, hospital and ICU stay, MV support, and CFR.</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Contribution of Biophysics and Structural Biology to Current Advances in COVID-19</strong> - Critical to viral infection are the multiple interactions between viral proteins and host-cell counterparts. The first such interaction is the recognition of viral envelope proteins by surface receptors that normally fulfil other physiological roles, a hijacking mechanism perfected over the course of evolution. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019 (COVID-19), has successfully adopted this strategy using its spike…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Role of epithelial-endothelial cell interaction in the pathogenesis of SARS-CoV-2 infection</strong> - CONCLUSIONS: This study evaluates the role of endothelial cells in the development of clinical disease caused by SARS-CoV-2, and the importance of endothelial cell-epithelial cell interaction in the pathogenesis of human COVID-19 diseases.</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Chloroquine and Hydroxychloroquine for the Prevention and Treatment of COVID-19: A Fiction, Hope or Hype? An Updated Review</strong> - In December 2019, the novel coronavirus disease pandemic (COVID-19) that began in China had infected so far more than 109,217,366 million individuals worldwide and accounted for more than 2,413,912 fatalities. With the dawn of this novel coronavirus (SARS-CoV-2), there was a requirement to select potential therapies that might effectively kill the virus, accelerate the recovery, or decrease the case fatality rate. Besides the currently available antiviral medications for human immunodeficiency…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Network pharmacology approach to decipher signaling pathways associated with target proteins of NSAIDs against COVID-19</strong> - Non-steroidal anti-inflammatory drugs (NSAIDs) showed promising clinical efficacy toward COVID-19 (Coronavirus disease 2019) patients as potent painkillers and anti-inflammatory agents. However, the prospective anti-COVID-19 mechanisms of NSAIDs are not evidently exposed. Therefore, we intended to decipher the most influential NSAIDs candidate(s) and its novel mechanism(s) against COVID-19 by network pharmacology. FDA (U.S. Food & Drug Administration) approved NSAIDs (19 active drugs and one…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys</strong> - SARS-CoV-2 caused the COVID-19 pandemic that lasted for more than a year. Globally, there is an urgent need to use safe and effective vaccines for immunization to achieve comprehensive protection against SARS-CoV-2 infection. Focusing on developing a rapid vaccine platform with significant immunogenicity as well as broad and high protection efficiency, we designed a SARS-CoV-2 spike protein receptor-binding domain (RBD) displayed on self-assembled ferritin nanoparticles. In a 293i cells…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Uncoupling of macrophage inflammation from self-renewal modulates host recovery from respiratory viral infection</strong> - Tissue macrophages self-renew during homeostasis and produce inflammatory mediators upon microbial infection. We examined the relationship between proliferative and inflammatory properties of tissue macrophages by defining the impact of the Wnt/β-catenin pathway, a central regulator of self-renewal, in alveolar macrophages (AMs) . Activation of β-catenin by Wnt ligand inhibited AM proliferation and stemness, but promoted inflammatory activity. In a murine influenza viral pneumonia model,…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Mechanistic insights into the inhibitory activity of FDA approved ivermectin against SARS-CoV-2: old drug with new implications</strong> - The novel corona virus (Covid-19) has become a great challenge worldwide since 2019, as no drug has been reported yet. Different clinical trials are still under way. Among them is Ivermectin (IVM), an FDA approved drug which was recently reported as a successful candidate to reduce SARS-CoV-2 viral load by inhibiting Importin-α1 (IMP-α1) protein which subsequently affects nuclear transport of viral proteins but its basic binding mode and inhibitory mechanism is unknown. Therefore, we aimed to…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Investigation of potential inhibitor properties of ethanolic propolis extracts against ACE-II receptors for COVID-19 treatment by molecular docking study</strong> - The angiotensin-converting enzyme (ACE)-related carboxypeptidase, ACE-II, is a type I integral membrane protein of 805 amino acids that contains 1 HEXXH-E zinc binding consensus sequence. ACE-II has been implicated in the regulation of heart function and also as a functional receptor for the coronavirus that causes the severe acute respiratory syndrome (SARS). In this study, the potential of some flavonoids presents in propolis to bind to ACE-II receptors was calculated with in silico. Binding…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>SARS-COV-2 induced Diarrhea is inflammatory, Ca (2+) Dependent and involves activation of calcium activated Cl channels</strong> - Diarrhea occurs in 2-50% of cases of COVID-19 (∼8% is average across series). The diarrhea does not appear to account for the disease mortality and its contribution to the morbidity has not been defined, even though it is a component of Long Covid or post-infectious aspects of the disease. Even less is known about the pathophysiologic mechanism of the diarrhea. To begin to understand the pathophysiology of COVID-19 diarrhea, we exposed human enteroid monolayers obtained from five healthy…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Great Deceiver: miR-2392’s Hidden Role in Driving SARS-CoV-2 Infection</strong> - MicroRNAs (miRNAs) are small non-coding RNAs involved in post-transcriptional gene regulation that have a major impact on many diseases and provides an exciting avenue towards antiviral therapeutics. From patient transcriptomic data, we have discovered a circulating miRNA, miR-2392, that is directly involved with SARS-CoV-2 machinery during host infection. Specifically, we found that miR-2392 was key in driving downstream suppression of mitochondrial gene expression, increasing inflammation,…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The SARS-CoV-2 protein ORF3a inhibits fusion of autophagosomes with lysosomes</strong> - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the ongoing coronavirus disease 2019 pandemic. How SARS-CoV-2 regulates cellular responses to escape clearance by host cells is unknown. Autophagy is an intracellular lysosomal degradation pathway for the clearance of various cargoes, including viruses. Here, we systematically screened 28 viral proteins of SARS-CoV-2 and identified that ORF3a strongly inhibited autophagic flux by blocking the fusion of autophagosomes with…</p></li>
|
||
</ul>
|
||
<h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
|
||
<ul>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>IMPROVEMENTS RELATED TO PARTICLE, INCLUDING SARS-CoV-2, DETECTION AND METHODS THEREFOR</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU323295937">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A COMPREHENSIVE DISINFECTION SYSTEM DURING PANDEMIC FOR PERSONAL ITEMS AND PROTECTIVE EQUIPMENT (PPE) TO SAFEGUARD PEOPLE</strong> - The current Covid-19 pandemic has led to an enormous demand for gadgets / objects for personal protection. To prevent the spread of virus, it is important to disinfect commonly touched objects. One of the ways suggested is to use a personal UV-C disinfecting box that is “efficient and effective in deactivating the COVID-19 virus. The present model has implemented the use of a UV transparent material (fused silica quartz glass tubes) as the medium of support for the objects to be disinfected to increase the effectiveness of disinfection without compromising the load bearing capacity. Aluminum foil, a UV reflecting material, was used as the inner lining of the box for effective utilization of the UVC light emitted by the UVC lamps. Care has been taken to prevent leakage of UVC radiation out of the system. COVID-19 virus can be inactivated in 5 minutes by UVC irradiation in this disinfection box - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN322882412">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>UBIQUITOUS COMPUTING SYSTEM FOR MENTAL HEALTH MONITORING OF PERSON DURING THE PANDEMIC OF COVID-19</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU323295498">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>USE OF IMINOSUGAR COMPOUND IN PREPARATION OF ANTI-SARS-COV-2 VIRUS DRUG</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU322897928">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU321590214">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>用于检测新型冠状病毒的试纸和试剂盒</strong> - 本发明涉及生物技术和免疫检测技术领域，具体涉及一种用于检测新型冠状病毒的试纸和试剂盒。所述试纸或试剂盒含有抗体1和/或抗体2，所述抗体1的重、轻链可变区的氨基酸序列分别如SEQ ID NO:1‑2所示，所述抗体2的重、轻链可变区的氨基酸序列分别如SEQ ID NO:3‑4所示。本发明对于大批量的新型冠状病毒样本，包括新型冠状病毒突变（英国、南非）与非突变株的人血清、鼻咽拭子等样本的检测有普遍检测意义，避免突变株的漏检。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN322953478">link</a></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Fahrgastleitsystem und Verfahren zum Leiten von Fahrgästen</strong> -
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Die Erfindung betrifft ein Fahrgastleitsystem zum Leiten von mit einem Fahrzeug (1) mit wenigstens zwei Türen (2.L, 2.R) transportieren Fahrgästen (3), mit wenigstens einem Sensor (4) zur Überwachung der Fahrgäste (3), wenigstens einem Anzeigemittel (5) zur Ausgabe von Leitinformationen, wenigstens einem Aktor zum Öffnen oder Verriegeln einer Tür (2.L, 2.R) und wenigstens einer Recheneinheit (7). Das erfindungsgemäße Fahrgastleitsystem ist dadurch gekennzeichnet, dass die Recheneinheit (7) dazu eingerichtet ist durch Auswertung vom wenigstens einen Sensor (4) erzeugter Sensordaten zu erkennen an welcher Tür (2.L, 2.R) des Fahrzeugs (1) Fahrgäste (3) ein- und/oder aussteigen möchten und wenigstens eine Tür (2.L, 2.R) für einen Ausstieg festzulegen und/oder wenigstens eine Tür (2.L, 2.R) für einen Einstieg festzulegen, sodass eine Anzahl an Begegnungen von sich durch das Fahrzeug (1) bewegender Fahrgäste (3) und/oder aus dem Fahrzeug (1) aussteigenden und/oder in das Fahrzeug (1) einsteigenden Fahrgästen (3) minimiert wird.</p></li>
|
||
</ul>
|
||
<img alt="embedded image" id="EMI-D00000"/>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
||
<ul>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=DE323289145">link</a></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Vorrichtung zum Desinfizieren, der Körperpflege oder dergleichen</strong> -
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Vorrichtung zum Desinfizieren, der Körperpflege oder dergleichen mittels einer flüssigen oder cremigen Substanz (20), dadurch gekennzeichnet, dass die Vorrichtung mit einem elektrisch betriebenen Erinnerungs-Modul und einem Vorratsbehälter (10) für die Substanz (20) versehen ist, die Substanz (20) in dosierter Menge zur Ausgabeöffnung (9) gefördert wird und die Vorrichtung dazu geeignet ist, am Körper oder der Kleidung einer Person getragen zu werden.</p></li>
|
||
</ul>
|
||
<img alt="embedded image" id="EMI-D00000"/>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
||
<ul>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=DE323289850">link</a></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Gebrauchter Schnellteststreifen als Probenmaterial für eine Nachtestung</strong> -
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Die Erfindung betrifft ein Verfahren zur laborbasierten Überprüfung und/oder weiteren Ausdifferenzierung einer im Schnelltestverfahren erhaltenen Diagnose einer Infektionskrankheit, wobei im Rahmen des Schnelltestverfahrens eine flüssige Patientenprobe auf ein Objekt aus einem porösen Material aufgetragen wird und wobei dieses Objekt nach Trocknung der flüssigen Patientenprobe an das diagnostische Labor übermittelt wird. Im Labor werden dann die eingetrockneten Probenreste aus dem porösen Material ausgelöst und analysiert.</p></li>
|
||
</ul>
|
||
<img alt="embedded image" id="EMI-D00000"/>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
||
<ul>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=DE323289151">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>针对新型冠状病毒核衣壳蛋白的抗体或其抗原结合片段及其应用</strong> - 本发明提供了一种针对新型冠状病毒核衣壳蛋白的抗体或其抗原结合片段及其应用，所述抗体选自mAb6抗体、mAb7抗体、mAb8抗体和mAb9抗体中的任意一种；且所述抗体由保藏号为CCTCC NO：C2020236、CCTCC NO：C2020237、CCTCC NO：C2020238或CCTCC NO：C2020239的杂交瘤细胞分泌。利用所述抗体能够检测环境样品和/或生物样品中新型冠状病毒或者其抗原的存在情况。此外，本发明还提供了利用所述抗体制备得到的新型冠状病毒检测试剂盒，能够在感染病毒早期就检测出核衣壳蛋白，为临床检测新型冠状病毒提供了快速、准确的手段。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN323191621">link</a></p></li>
|
||
</ul>
|
||
|
||
|
||
<script>AOS.init();</script></body></html> |